Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products through acquisitions or licensing. Their commercial capabilities include marketing via sales force and non-personal promotion, market access through payor contracting, and trade and distribution. Key products include ROLVEDON (eflapegrastim-xnst) injection, INDOCIN (indomethacin) Suppositories and Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution), and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN products are NSAIDs. We show 29 historical shares outstanding datapoints in our coverage of ASRT's shares outstanding history.
Understanding the changing numbers of ASRT shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ASRT versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ASRT by allowing them to research ASRT shares outstanding history
as well as any other stock in our coverage universe. |
Free ASRT Email Alerts:
Video: Shares Outstanding Importance
